九洲藥業(603456.SH):奧卡西平片、卡馬西平膠囊獲得藥品生產許可證
格隆匯9月3日丨九洲藥業(603456.SH)公佈,近日,公司全資子公司浙江四維醫藥科技有限公司(“四維醫藥”)收到浙江省藥品監督管理局頒發的《藥品生產許可證》。涉及生產線產能為:

截止公吿日,上述生產線建設已投入約6065.84萬元。
奧卡西平片適用於治療原發性全面性強直-陣攣發作和部分性發作,伴有或不伴有繼發性全面性發作。目前該產品國內主要生產企業為武漢人福藥業有限責任公司、北京四環製藥有限公司等。公司未能從公開渠道獲得該產品總體市場的銷售數據。
卡馬西平膠囊適用於複雜部分性發作、全身強直-陣攣性發作等。目前該產品國內主要生產企業為華潤三九(北京)藥業有限公司、華北製藥股份有限公司等。根據《2020-2025年中國抗癲癇藥物市場運行態勢及行業發展前景預測報吿》顯示,2018年全球抗癲癇藥物製劑銷售額高達194.96億美元,公司未能從公開渠道獲得該產品總體市場的銷售數據。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.